98%
921
2 minutes
20
Lockdown caused by COVID-19 pandemic has a negative impact on mental health. The aim was to assess self-reported neurocognitive symptoms during the lockdown and identify associated vulnerable and protective factors in a sample of psychiatric patients in a Spanish population. These results are part of the Barcelona ResIlience Survey for Mental Health COVID-19 (BRIS-MHC) project. Neurocognitive symptoms were assessed through an online survey considering the five items that represented self-reported neurocognitive complaints. We split the sample into two groups based on the severity of the self-reported neurocognitive complaints: intact cognitive function/mild cognitive impairment (CI-) and moderate/severe cognitive impairment (CI+). Univariate analyses were used to compare both groups in terms of sociodemographic and clinical variables. Multiple logistic regression models were carried out to identify clinical variables and coping strategies associated with neurocognitive symptoms. 198 patients with different psychiatric diagnoses were included in this study. One hundred seventeen patients were classified in the CI- group and 81 in the CI+ group. Depressive symptoms and negative psychotic-like symptoms were vulnerable factors for neurocognitive impairment. Coping strategies of performing physical activity, carrying out relaxing activities and maintaining a routine were protective factors against cognitive impairment. Lockdown situation negatively impact on neurocognitive function. Psychopathological symptoms and coping strategies were associated with neurocognitive symptoms during lockdown in subjects with psychiatric illness. The early treatment of psychopathological symptoms in psychiatric patients and promoting coping strategies during lockdown should be considered an intervention strategy against cognitive impairment.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619656 | PMC |
http://dx.doi.org/10.1016/j.euroneuro.2021.07.006 | DOI Listing |
Acta Neurochir (Wien)
September 2025
Gui de Chauliac Hospital, Montpellier University Medical Center, Montpellier, France.
Background: Awake surgery is the reference for diffuse low-grade glioma resection, allowing maximal tumor removal while preserving neurocognitive functions. It is also applicable to other brain tumors. However, key technical elements must be followed to ensure optimal conditions for intraoperative cognitive testing and reliable functional mapping.
View Article and Find Full Text PDFBiol Psychiatry Cogn Neurosci Neuroimaging
September 2025
Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center. Electronic address:
Background: The interthalamic adhesion (IA) is a midline structure connecting the left and right thalamus that typically develops during the 2 trimester of pregnancy. Missing and smaller IA has been linked to neurodevelopmental disorders, including schizophrenia, and subtle deficits in cognition. However, findings are inconsistent and the association between IA and other anatomical variants linked to atypical brain development in schizophrenia, including incomplete hippocampal inversion (IHI), is unclear.
View Article and Find Full Text PDFJAMA Netw Open
September 2025
Department of Neurosciences, University of California, San Diego, La Jolla.
Importance: Subjective cognitive decline (SCD) may be an early indicator of Alzheimer disease and related dementias (ADRD), yet its association with plasma biomarkers remains unclear among middle-aged and older adults (aged 50-86 years).
Objective: To examine associations between plasma biomarkers of amyloid, tau, neuroaxonal damage, and glial activation with SCD in a heterogeneous cohort of Hispanic and/or Latino adults.
Design, Setting, And Participants: This cross-sectional study used survey-weighted data from the Study of Latinos-Investigation of Neurocognitive Aging, an ancillary study of the Hispanic Community Health Study/Study of Latinos.
Wien Klin Wochenschr
September 2025
Department of Neurology, Medical University of Vienna, Vienna, Austria.
Background: Disease-modifying therapies with amyloid-antibodies will soon be available for patients with early Alzheimer's disease, which necessitates diagnostic and therapeutic resources in hospital and outpatient settings.
Methods: The Austrian Alzheimer Society developed an online questionnaire to survey Austrian hospital-based departments of neurology and psychiatry regarding resources for amyloid-antibody therapies.
Results: Between May and October 2023, 30 out of 41 neurology (73%) and 12 out of 33 psychiatry departments (36%) responded.
Front Cell Infect Microbiol
September 2025
Fundació Lluita contra les Infeccions, Badalona, Spain.
Background: The intestinal microbiota composition has been linked to neurocognitive impairment in people with HIV (PWH). However, the potential interplay of microbial species and related metabolites, particularly in the context of an HIV cure strategy remains underexplored. The BCN02 trial evaluated the impact of romidepsin (RMD), used as a HIV-1 latency reversing agent and with reported beneficial neurological effects, combined with the MVA.
View Article and Find Full Text PDF